NO932423D0 - Ekspresjon av rekombinante proteiner i attenuerte bakterier - Google Patents
Ekspresjon av rekombinante proteiner i attenuerte bakterierInfo
- Publication number
- NO932423D0 NO932423D0 NO932423A NO932423A NO932423D0 NO 932423 D0 NO932423 D0 NO 932423D0 NO 932423 A NO932423 A NO 932423A NO 932423 A NO932423 A NO 932423A NO 932423 D0 NO932423 D0 NO 932423D0
- Authority
- NO
- Norway
- Prior art keywords
- attenuated
- expression
- bacteries
- recombinant proteins
- heterologous protein
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 abstract 2
- 101150044129 nirB gene Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919104596A GB9104596D0 (en) | 1991-03-05 | 1991-03-05 | Production of recombinant proteins |
| GB919121208A GB9121208D0 (en) | 1991-10-04 | 1991-10-04 | Vaccines |
| PCT/GB1992/000387 WO1992015689A1 (en) | 1991-03-05 | 1992-03-05 | Expression of recombinant proteins in attenuated bacteria |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO932423L NO932423L (no) | 1993-07-02 |
| NO932423D0 true NO932423D0 (no) | 1993-07-02 |
| NO309331B1 NO309331B1 (no) | 2001-01-15 |
Family
ID=26298523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO932423A NO309331B1 (no) | 1991-03-05 | 1993-07-02 | Vaksine inneholdende attenuerte bakterier og anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US5547664A (no) |
| EP (1) | EP0574466B1 (no) |
| JP (1) | JP3415145B2 (no) |
| KR (1) | KR100240182B1 (no) |
| AT (1) | ATE180280T1 (no) |
| AU (1) | AU664360B2 (no) |
| CA (1) | CA2099841C (no) |
| CZ (1) | CZ285118B6 (no) |
| DE (1) | DE69229221T2 (no) |
| DK (1) | DK0574466T3 (no) |
| ES (1) | ES2131069T3 (no) |
| FI (1) | FI110008B (no) |
| GR (1) | GR3030778T3 (no) |
| HU (1) | HU219535B (no) |
| NO (1) | NO309331B1 (no) |
| PL (1) | PL170938B1 (no) |
| SK (1) | SK55593A3 (no) |
| WO (1) | WO1992015689A1 (no) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9209118D0 (en) * | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
| KR950702635A (ko) * | 1992-07-31 | 1995-07-29 | 크리스틴 헬렌 수덴 | 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria) |
| CA2168459C (en) * | 1993-07-30 | 2002-10-01 | Mohammed Anjam Khan | Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein |
| GB9401787D0 (en) | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccine compositions |
| GB9401795D0 (en) * | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccines |
| GB2295394B (en) * | 1994-01-31 | 1997-09-24 | Medeva Holdings Bv | DNA encoding a fusion protein comprising the C fragment of tetanus toxin |
| AUPM612494A0 (en) * | 1994-06-08 | 1994-06-30 | Csl Limited | Treatment or prevention of helicobacter infection |
| US6254874B1 (en) * | 1995-04-13 | 2001-07-03 | President And Fellows Of Harvard College | Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same |
| US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| CN1253551C (zh) | 1997-09-10 | 2006-04-26 | 维昂药品公司 | 减毒的遗传修饰肿瘤靶向细菌 |
| US6905691B1 (en) | 1997-12-11 | 2005-06-14 | Celltech Pharma Europe Limited | Vaccines containing attenuated bacteria |
| GB9806449D0 (en) * | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6585975B1 (en) * | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
| FR2778922A1 (fr) * | 1998-05-19 | 1999-11-26 | Pasteur Institut | Polynucleotides contenant des sequences de regulation de la synthese de toxines de clostridium, et microorganismes les comprenant |
| US6413768B1 (en) * | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| EP1860117A3 (en) | 1999-04-09 | 2008-09-03 | Pharmacia & Upjohn Company LLC | Anti-bacterial vaccine compositions |
| US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| GB0024203D0 (en) * | 2000-10-03 | 2000-11-15 | Peptide Therapeutics Ltd | Stabilisation of plasmid inheritance in bacteria |
| AU2002213681A1 (en) * | 2000-11-09 | 2002-05-21 | The University Of Queensland | Bacterial expression systems |
| US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| GB0121998D0 (en) | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
| AUPR977601A0 (en) * | 2001-12-28 | 2002-01-31 | Delta Biotechnology Limited | Defective entities and uses therefor |
| GB0205376D0 (en) * | 2002-03-07 | 2002-04-24 | Royal Holloway University Of L | Spore germination |
| AU2003250250B2 (en) * | 2002-06-19 | 2008-02-14 | Intrexon Actobiotics Nv | Methods and means to promote gut absorption |
| EP1560935A2 (en) * | 2002-11-15 | 2005-08-10 | VIB vzw | Self-containing lactobacillus strain |
| CN101048181A (zh) | 2004-08-13 | 2007-10-03 | 巴里·J·马沙尔 | 细菌递送系统 |
| US8029777B2 (en) | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
| JP5410759B2 (ja) | 2005-11-29 | 2014-02-05 | アクトジェニックス・エヌブイ | 抗原に対する粘膜寛容の誘導 |
| CN101522210B (zh) | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| EP2125010B1 (en) | 2007-01-25 | 2014-06-04 | Actogenix N.V. | Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus |
| NZ585776A (en) * | 2007-10-30 | 2012-07-27 | Univ Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PL2214701T3 (pl) * | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| UA110024C2 (uk) | 2010-01-21 | 2015-11-10 | Вакцинний вектор і спосіб посилення імунної відповіді | |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| KR102007132B1 (ko) | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| CN102477440A (zh) * | 2010-11-29 | 2012-05-30 | 南京大学 | 治疗基因在厌氧组织靶向递送和选择性稳定表达方法及应用 |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| ES2645156T3 (es) | 2011-03-21 | 2017-12-04 | Altimmune Inc. | Agente terapéutico inmunológico de acción rápida y prolongada |
| NZ711019A (en) | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| EP2968423A4 (en) | 2013-03-15 | 2016-11-09 | Univ Arkansas | COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
| DE3735381A1 (de) * | 1987-03-31 | 1989-05-03 | Boehringer Mannheim Gmbh | Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen |
| GB8730037D0 (en) * | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
| JPH0284172A (ja) * | 1988-07-21 | 1990-03-26 | Smithkline Beckman Corp | 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体 |
| DE3926076A1 (de) * | 1989-04-21 | 1990-10-25 | Boehringer Mannheim Gmbh | Rekombinante dna und expressionsvektor |
| GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| GB9007194D0 (en) * | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| GB9104596D0 (en) * | 1991-03-05 | 1991-04-17 | Wellcome Found | Production of recombinant proteins |
-
1992
- 1992-03-05 KR KR1019930702594A patent/KR100240182B1/ko not_active IP Right Cessation
- 1992-03-05 WO PCT/GB1992/000387 patent/WO1992015689A1/en active IP Right Grant
- 1992-03-05 PL PL92296702A patent/PL170938B1/pl unknown
- 1992-03-05 DK DK92905914T patent/DK0574466T3/da active
- 1992-03-05 DE DE69229221T patent/DE69229221T2/de not_active Expired - Lifetime
- 1992-03-05 CA CA002099841A patent/CA2099841C/en not_active Expired - Lifetime
- 1992-03-05 SK SK55593A patent/SK55593A3/sk unknown
- 1992-03-05 CZ CZ931005A patent/CZ285118B6/cs not_active IP Right Cessation
- 1992-03-05 AU AU13508/92A patent/AU664360B2/en not_active Expired
- 1992-03-05 AT AT92905914T patent/ATE180280T1/de active
- 1992-03-05 JP JP50556392A patent/JP3415145B2/ja not_active Expired - Lifetime
- 1992-03-05 EP EP92905914A patent/EP0574466B1/en not_active Expired - Lifetime
- 1992-03-05 ES ES92905914T patent/ES2131069T3/es not_active Expired - Lifetime
- 1992-03-05 HU HU9302492A patent/HU219535B/hu unknown
-
1993
- 1993-07-02 NO NO932423A patent/NO309331B1/no not_active IP Right Cessation
- 1993-08-26 FI FI933757A patent/FI110008B/fi not_active IP Right Cessation
-
1994
- 1994-12-12 US US08/354,776 patent/US5547664A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/469,507 patent/US5683700A/en not_active Expired - Lifetime
-
1999
- 1999-07-14 GR GR990401865T patent/GR3030778T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9302492D0 (en) | 1993-11-29 |
| GR3030778T3 (en) | 1999-11-30 |
| CZ285118B6 (cs) | 1999-05-12 |
| NO932423L (no) | 1993-07-02 |
| EP0574466A1 (en) | 1993-12-22 |
| DE69229221T2 (de) | 1999-09-23 |
| PL296702A1 (en) | 1993-07-26 |
| HUT66833A (en) | 1995-01-30 |
| JP3415145B2 (ja) | 2003-06-09 |
| AU1350892A (en) | 1992-10-06 |
| WO1992015689A1 (en) | 1992-09-17 |
| FI110008B (fi) | 2002-11-15 |
| EP0574466B1 (en) | 1999-05-19 |
| ES2131069T3 (es) | 1999-07-16 |
| JPH06505158A (ja) | 1994-06-16 |
| AU664360B2 (en) | 1995-11-16 |
| DK0574466T3 (da) | 1999-11-08 |
| CA2099841C (en) | 2003-02-25 |
| US5683700A (en) | 1997-11-04 |
| HU219535B (hu) | 2001-05-28 |
| FI933757A (fi) | 1993-08-26 |
| PL170938B1 (pl) | 1997-02-28 |
| NO309331B1 (no) | 2001-01-15 |
| SK55593A3 (en) | 1993-10-06 |
| FI933757A0 (fi) | 1993-08-26 |
| US5547664A (en) | 1996-08-20 |
| DE69229221D1 (de) | 1999-06-24 |
| ATE180280T1 (de) | 1999-06-15 |
| KR100240182B1 (ko) | 2000-01-15 |
| CZ100593A3 (en) | 1994-01-19 |
| CA2099841A1 (en) | 1992-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO932423L (no) | Ekspresjon av rekombinante proteiner i attenuerte bakterier | |
| EA199700244A1 (ru) | Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат | |
| EA199800973A1 (ru) | Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение | |
| DK0524205T3 (da) | Levende vacciner | |
| LV5288A3 (lv) | Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1 | |
| NO180239C (no) | Ekspresjonsvektor som koder for, og kan uttrykke et polypeptid med de biologiske og immunologiske egenskapene til EqIFN-<gamma>, vertsorganisme transformert med denne, og fremgangsmåte for fremstilling av nevnte polypeptid | |
| FI863891A (fi) | Menetelmiä sekropiinin ja muiden heterologisten polypeptidien tuottamiseksi bakteeri-isännässä araB-promoottoria käyttäen sekä menetelmissä käyttökelpoisia replikoituvia ekspressiovälineitä, geneettisiä muodostelmia ja bakteereja | |
| EP0257721A3 (en) | Vaccine | |
| DK0546833T3 (da) | Calciumreguleret promotor | |
| DE68924649D1 (de) | Allelische varianten von -i(plasmodium falciparum) merozoit-oberflächen-antigen. | |
| PT742829E (pt) | Expressao de proteinas heterologas em bacterias atenuadas utilizando os promotores htra | |
| DK230890A (da) | Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |